News

The company has also reported that the USPTO has issued US Patent No 7666415, covering bispecific antibody constructs incorporating the company’s proprietary histamine-succinyl-glycine (HSG)-binding 679 antibody. Cynthia Sullivan,

AVAGAST is a multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate Avastin plus Xeloda (capecitabine) or 5-FU and cisplatin chemotherapy compared to Xeloda or 5-FU and

The three-year award totaling approximately $3m will support collaborative research by investigators at Sanaria and Columbia University. The new funding extends previous NIAID supported efforts at Sanaria and

The FDA approved Bioguard is a non-leaching antimicrobial dressing and had its first commercial sale of the product in June 2009. The dressings serve as a barrier to

However, FDA has added information to the Specific Populations section of the product label under ‘Heart Failure’ stating that in a placebo-controlled trial of 2,128 patients (1,067 with

Galapagos said that the Phase I studies for GLPG0259 have shown a good safety profile in healthy volunteers and confirm a once-daily oral dosing regimen. Furthermore, the studies

In addition to providing the capability to conduct a variety of studies in healthy volunteers, the core focus of the Port Elizabeth unit is on early phase studies

NEBNext reagents are a series of highly pure reagents that facilitate sample preparation for downstream applications, such as next generation sequencing. All reagents undergo stringent quality controls and

Source BioScience will provide infrastructure and technology platforms in addition to employing technical staff and expertise to operate the Dublin facility, with further support available from its main